explore -WSS

explore

author：Wikipedia 2025-08-11 08:00:45 - browse：18696

Cambridge: Biogen — Ruby Wallau for STAT

A plan to use new genetic techniques to treat non-genetic forms of ALS failed in an early study, Ionis and Biogen announced Thursday. The companies said they would discontinue the program.

In the randomized, 99-person trial, the companies tested a drug designed to silence a gene called ATXN2. Over the last decade, numerous drugs have been built to silence genes in ALS patients, but most of them have, fittingly, focused on rare genetic forms of ALS, where neurons die largely because of the work of a single mutated stretch of DNA.

This approach has led to an approved drug for one very small subset of ALS cases, driven by the gene SOD1, and drugs for other genes are in trials. But only perhaps 10% — or at most 20% — of ALS cases are genetic. The hope, based on some genetic data and promising mice experiments, was that lowering ATXN2 would help any patient who develops ALS.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： CDC director unscathed in first congressional testimony

leisure time

WSS

The EPA's new lead rule: How one expert crunched the numbers

PBM reforms clear House panel

Congress must reauthorize a committee to support older Americans

Surge of respiratory disease in China has likely explanation

U.K. Biobank has 500,000 peoples' genome sequences available

CRISPR pioneers react to Casgevy, first gene

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

A daunting task: navigating dual Medicare, Medicaid eligibility

How to save PrEP access — and even expand it

Hospitals look to new technology to keep health care workers safe

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

World's first CRISPR

What does generative AI mean for health care? We asked experts

Organ aging and disease risk measured by new blood test

Trump demands the U.S. pay no more for drugs than other countries … again

U.K. Biobank has 500,000 peoples' genome sequences available

knowledge

What to do when lifesaving products contribute to climate change

CDC director unscathed in first congressional testimony

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Wikipedia

hotspot

leisure time

hotspot